Mesoderm and definitive endoderm cell populations

• US 20080226558A1
• Filed: 03/24/2008
• Published: 09/18/2008
• Est. Priority Date: 05/17/2002
• Status: Active Grant

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG), Mount Sinai School of Medicine (Sinai Health System)
• Original Assignee: Icahn School of Medicine at Mount Sinai
• Inventors: Keller, Gordon M., Fehling, Hans Joerg, Kubo, Atsushi, Kouskoff, Valerie
• Granted Patent: US 7,955,849 B2
• Time in Patent Office: Days
• US Class Current: 424/9.1
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0603 Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: G01N 33/5073 Stem cells

Abstract

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.

Claims

1-19. -19. (canceled)

20. A method of isolating a cell population enriched for mesoderm cells comprising culturing embryonic stem cells in the absence of serum and in the presence of activin in an amount sufficient to induce differentiation of embryonic stem cells to mesoderm but insufficient to induce differentiation of embryonic stems cells to endoderm, and isolating cells that express brachyury.

31. A cell population enriched for mesoderm cells produced by the method of claim 20.

21-30. -30. (canceled)

32. A method of generating a cell population enriched for mesoderm cells comprising culturing embryonic stem cells in the presence of a concentration of activin sufficient to induce differentiation of embryonic stem cells to mesoderm but insufficient to induce differentiation of embryonic stem cells to endoderm.

33. The method of claim 32 wherein the concentration of activin is less than about 30 ng/ml.

34. The method of claim 33 wherein the embryonic stem cells are human embryonic stem cells.

35. A cell population enriched for mesoderm produced by the method of claim 32.

36. A cell population enriched for mesoderm produced by the method of claim 33.

37. A cell population enriched for mesoderm produced by the method of claim 34.